Obinutuzumab for kidney disease

Membranous nephropathy is a common cause of nephrotic syndrome in adults. Rituximab is a type I anti-CD20 antibody that has been shown to be an effective treatment for patients with M-type phospholipase A2 receptor (PLA2R) antibody-associated MN. Despite its efficacy, up to 40% of patients may not respond to rituximab, which may be related to higher PLA2R antibody titers.

Obinutuzumab, a type II anti-CD20 depleting agent, has been shown to produce deeper CD20 depletion and be more effective in treating certain hematological malignancies compared with rituximab. Clinical studies reported 3 patients with PLA2R-associated MN in whom rituximab failed to induce immune or clinical remission, but who were successfully treated with otuzumab. Otuzumab resulted in complete immune remission in all 3 cases, followed by partial remission in 2 cases. Otuzumab appears to be a promising therapeutic strategy for PLA2R-related MN refractory to rituximab.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.